1
|
Ho-Le TP, Tran HTT, Center JR, Eisman JA, Nguyen HT, Nguyen TV. Assessing the clinical utility of genetic profiling in fracture risk prediction: a decision curve analysis. Osteoporos Int 2021; 32:271-280. [PMID: 32789607 DOI: 10.1007/s00198-020-05403-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2020] [Accepted: 03/23/2020] [Indexed: 10/23/2022]
Abstract
UNLABELLED Using decision curve analysis on 2188 women and 1324 men, we found that an osteogenomic profile constructed from 62 genetic variants improved the clinical net benefit of fracture risk prediction over and above that of clinical risk factors and BMD. INTRODUCTION Genetic profiling is a promising tool for assessing fracture risk. This study sought to use the decision curve analysis (DCA), a novel approach to determine the impact of genetic profiling on fracture risk prediction. METHODS The study involved 2188 women and 1324 men, aged 60 years and above, who were followed for up to 23 years. Bone mineral density (BMD) and clinical risk factors were obtained at baseline. The incidence of fracture and mortality were recorded. A weighted individual genetic risk score (GRS) was constructed from 62 BMD-associated genetic variants. Four models were considered: CRF (clinical risk factors); CRF + GRS; Garvan model (GFRC) including CRF and femoral neck BMD; and GFRC + GRS. The DCA was used to evaluate the clinical net benefit of predictive models at a range of clinically reasonable risk thresholds. RESULTS In both women and men, the full model GFRC + GRS achieved the highest net benefits. For 10-year risk threshold > 18% for women and > 15% for men, the GRS provided net benefit above those of the CRF models. At 20% risk threshold, adding the GRS could help to avoid 1 additional treatment per 81 women or 1 per 24 men compared with the Garvan model. At lower risk thresholds, there was no significant difference between the four models. CONCLUSIONS The addition of genetic profiling into the clinical risk factors can improve the net clinical benefit at higher risk thresholds of fracture. Although the contribution of genetic profiling was modest in the presence of BMD + CRF, it appeared to be able to replace BMD for fracture prediction.
Collapse
Affiliation(s)
- T P Ho-Le
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, Australia
- Faculty of Science, Engineering and Technology, Swinburne University of Technology, Melbourne, Australia
- Faculty of Engineering and Information Technology, Hatinh University, Hatinh, Vietnam
| | - H T T Tran
- Faculty of Engineering and Information Technology, Hatinh University, Hatinh, Vietnam
| | - J R Center
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, Australia
- St Vincent Clinical School, UNSW Sydney, Sydney, Australia
| | - J A Eisman
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, Australia
- St Vincent Clinical School, UNSW Sydney, Sydney, Australia
- School of Medicine Sydney, University of Notre Dame Australia, Sydney, Australia
| | - H T Nguyen
- Faculty of Science, Engineering and Technology, Swinburne University of Technology, Melbourne, Australia
| | - T V Nguyen
- Healthy Ageing Theme, Garvan Institute of Medical Research, Sydney, Australia.
- St Vincent Clinical School, UNSW Sydney, Sydney, Australia.
- School of Medicine Sydney, University of Notre Dame Australia, Sydney, Australia.
- School of Biomedical Engineering, University of Technology, Sydney, Australia.
| |
Collapse
|
2
|
Truong AD, Hong Y, Nguyen HT, Nguyen CT, Chu NT, Tran HTT, Dang HV, Lillehoj HS, Hong YH. Molecular identification and characterisation of a novel chicken leukocyte immunoglobulin-like receptor A5. Br Poult Sci 2020; 62:68-80. [PMID: 32812773 DOI: 10.1080/00071668.2020.1812524] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
1. Leukocyte immunoglobulin-like receptor A5 (LILRA5) is a key molecule that regulates the immune system. However, the LILRA5 gene has not been characterised in avian species, including chickens. The present study aimed to identify and functionally characterise LILRA5 identified from two genetically disparate chicken lines, viz., Marek's disease (MD)-resistant (R) line 6.3 and MD-susceptible (S) line 7.2. 2. Multiple sequence alignment and phylogenetic analyses confirmed that the identity and similarity homologies of amino acids of LILRA5 in chicken lines 6.3 and 7.2 ranged between 93% and 93.7%, whereas those between chicken and mammals ranged between 20.9% and 43.7% and 21.1% to 43.9%, respectively. The newly cloned LILRA5 from chicken lines 6.3 and 7.2 revealed high conservation and a close relationship with other known mammalian LILRA5 proteins. 3. The results indicated that LILRA5 from chicken lines 6.3 and 7.2 was associated with phosphorylation of Src kinases and protein tyrosine phosphatase non-receptor type 11 (SHP2), which play a regulatory role in immune functions. Moreover, the results demonstrated that LILRA5 in these lines was associated with the activation of major histocompatibility complex (MHC) class I and β2-microglobulin and induced the expression of the transporter associated with antigen processing. In addition, LILRA5 in both chicken lines activated and induced Janus kinase (JAK)-signal transducer and the activator of transcription (STAT), nuclear factor kappa B (NF-κB), phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT) and the extracellular signal-regulated kinase (ERK)1/2 signalling pathways; toll-like receptors; and Th1-, Th2-, and Th17- cytokines. 4. The data suggested that LILRA5 has innate immune receptors essential for macrophage immune response and provide novel insights into the regulation of immunity and immunopathology.
Collapse
Affiliation(s)
- A D Truong
- Department of Biochemistry and Immunology, National Institute of Veterinary Research , Dong Da, Hanoi, Vietnam.,Department of Animal Science and Technology, Chung-Ang University , Anseong, Republic of Korea
| | - Y Hong
- Department of Animal Science and Technology, Chung-Ang University , Anseong, Republic of Korea
| | - H T Nguyen
- Department of Biochemistry and Immunology, National Institute of Veterinary Research , Dong Da, Hanoi, Vietnam
| | - C T Nguyen
- Department of Biochemistry and Immunology, National Institute of Veterinary Research , Dong Da, Hanoi, Vietnam
| | - N T Chu
- Department of Biochemistry and Immunology, National Institute of Veterinary Research , Dong Da, Hanoi, Vietnam
| | - H T T Tran
- Department of Biochemistry and Immunology, National Institute of Veterinary Research , Dong Da, Hanoi, Vietnam
| | - H V Dang
- Department of Biochemistry and Immunology, National Institute of Veterinary Research , Dong Da, Hanoi, Vietnam
| | - H S Lillehoj
- United States Department of Agriculture, Animal Biosciences and Biotechnology Laboratory, Agricultural Research Services , Beltsville, MD, USA
| | - Y H Hong
- Department of Animal Science and Technology, Chung-Ang University , Anseong, Republic of Korea
| |
Collapse
|
3
|
Pham KC, Tran HTT, Van Doan C, Le PH, Van Nguyen AT, Nguyen HA, Hong HA, Cutting SM, Phan TN. Protection of Penaeus monodon against white spot syndrome by continuous oral administration of a low concentration of Bacillus subtilis spores expressing the VP28 antigen. Lett Appl Microbiol 2017; 64:184-191. [PMID: 27992657 DOI: 10.1111/lam.12708] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2016] [Revised: 10/19/2016] [Accepted: 12/12/2016] [Indexed: 11/28/2022]
Abstract
In this study, Bacillus subtilis spores expressing a chimeric protein, CotB-VP28, were used as a probiotic vaccine to protect black tiger shrimps (Penaeus monodon) against white spot syndrome virus (WSSV) infection. Oral administration of pellets coated with CotB-VP28 spores (at ≥1 × 109 CFU per g pellet) to shrimps induced immune-relating phenoloxydase activity (PO) in shrimps after 14 days of feeding (prior challenge) and at day 3 post challenge (1·26 and 1·70 fold increase respectively). A 75% protection rate was obtained by continuous feeding of the spore-coated pellets at ≥1 × 109 CFU per g for 14 days prior to WSSV challenge and during all the postchallenge period. Even when the amount of CotB-VP28 spores in feed pellets was reduced down to ≥5 × 107 CFU per g and ≥1 × 106 CFU per g, relatively high protection rates of 70 and 67·5%, respectively, were still obtained. By contrast, feeding pellets without spores (untreated group) and with naked spores (PY79 group) at ≥1 × 109 CFU per g could not protect shrimps against WSSV. These data suggest that supplementation of CotB-VP28 spores at low dose of ≥1 × 106 CFU per g could be effective as a prophylactic treatment of WSS for black tiger shrimps. SIGNIFICANCE AND IMPACT OF THE STUDY This study reports the protective efficacy of Bacillus subtilis CotB-VP28 spores on black tiger shrimps (Penaeus monodon) against white spot syndrome virus infection. Oral administration of pellets coated with CotB-VP28 spores (≥1 × 109 CFU per g) conferred 75% protection after white spot syndrome virus challenge. Even after reducing CotB-VP28 spores in feed pellets to ≥1 × 106 CFU per g, 67·5% protections was still obtained. These data indicate that supplementation of CotB-VP28 spores at a low dose of ≥1 × 106 CFU per g could be effective in prophylaxis against white spot syndrome in black tiger shrimps.
Collapse
Affiliation(s)
- K-C Pham
- Key Laboratory of Enzyme and Protein Technology, VNU University of Science, Hanoi, Vietnam.,Department of Biochemistry, Institute of New Technology, Hanoi, Vietnam
| | - H T T Tran
- Faculty of Aquaculture, Can Tho University, Can Tho, Vietnam
| | - C Van Doan
- Southern Monitoring Center for Aquaculture Environment and Epidemic, Research Institute for Aquaculture No. 2, Ho Chi Minh City, Vietnam
| | - P H Le
- Southern Monitoring Center for Aquaculture Environment and Epidemic, Research Institute for Aquaculture No. 2, Ho Chi Minh City, Vietnam
| | - A T Van Nguyen
- Key Laboratory of Enzyme and Protein Technology, VNU University of Science, Hanoi, Vietnam
| | - H A Nguyen
- ANABIO Research & Development JSC, Hanoi, Vietnam
| | - H A Hong
- School of Biological Sciences, Royal Holloway University of London, Egham, UK
| | - S M Cutting
- School of Biological Sciences, Royal Holloway University of London, Egham, UK
| | - T-N Phan
- Key Laboratory of Enzyme and Protein Technology, VNU University of Science, Hanoi, Vietnam
| |
Collapse
|
4
|
Tran HTT, Sørensen B, Bjørnsen S, Pripp AH, Tjønnfjord GE, Andre Holme P. Monitoring bypassing agent therapy – a prospective crossover study comparing thromboelastometry and thrombin generation assay. Haemophilia 2014; 21:275-283. [DOI: 10.1111/hae.12570] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/21/2014] [Indexed: 01/24/2023]
Affiliation(s)
- H. T. T. Tran
- Research Institute of Internal Medicine Oslo University Hospital Oslo Norway
- Department of Haematology Oslo University Hospital Oslo Norway
- Institute of Clinical Medicine University of Oslo Oslo Norway
| | | | - S. Bjørnsen
- Research Institute of Internal Medicine Oslo University Hospital Oslo Norway
| | - A. H. Pripp
- Research Institute of Internal Medicine Oslo University Hospital Oslo Norway
- Department of Biostatistics and Epidemiology Oslo University Hospital Oslo Norway
| | - G. E. Tjønnfjord
- Department of Haematology Oslo University Hospital Oslo Norway
- Institute of Clinical Medicine University of Oslo Oslo Norway
| | - P. Andre Holme
- Research Institute of Internal Medicine Oslo University Hospital Oslo Norway
- Department of Haematology Oslo University Hospital Oslo Norway
- Institute of Clinical Medicine University of Oslo Oslo Norway
| |
Collapse
|
5
|
Tran HTT, Sørensen B, Rea CJ, Bjørnsen S, Ueland T, Pripp AH, Tjønnfjord GE, Holme PA. Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors. Haemophilia 2013; 20:369-75. [DOI: 10.1111/hae.12318] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/18/2013] [Indexed: 12/25/2022]
Affiliation(s)
- H. T. T. Tran
- Research Institute of Internal Medicine; Oslo University Hospital; Rikshospitalet; Oslo Norway
- Institute of Clinical Medicine; University of Oslo; Oslo Norway
- Department of Haematology; Oslo University Hospital; Rikshospitalet; Oslo Norway
| | - B. Sørensen
- Baxter Healthcare Corporation; Westlake Village CA USA
- Haemostasis Research Unit; Guy's and St Thomas' Hospital; London UK
| | - C. J. Rea
- Haemostasis Research Unit; Guy's and St Thomas' Hospital; London UK
| | - S. Bjørnsen
- Research Institute of Internal Medicine; Oslo University Hospital; Rikshospitalet; Oslo Norway
| | - T. Ueland
- Faculty of Medicine; University of Oslo; Oslo Norway
| | - A. H. Pripp
- Department of Biostatistics and Epidemiology; Oslo University Hospital; Oslo Norway
| | - G. E. Tjønnfjord
- Institute of Clinical Medicine; University of Oslo; Oslo Norway
- Department of Haematology; Oslo University Hospital; Rikshospitalet; Oslo Norway
| | - P. A. Holme
- Research Institute of Internal Medicine; Oslo University Hospital; Rikshospitalet; Oslo Norway
- Institute of Clinical Medicine; University of Oslo; Oslo Norway
- Department of Haematology; Oslo University Hospital; Rikshospitalet; Oslo Norway
| |
Collapse
|
6
|
|
7
|
Tran HTT, Tjønnfjord GE, Holme PA. Use of thromboelastography and thrombin generation assay to predict clinical phenotype in patients with severe FVII deficiency. Haemophilia 2013; 20:141-6. [DOI: 10.1111/hae.12256] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/21/2013] [Indexed: 01/08/2023]
Affiliation(s)
- H. T. T. Tran
- Research Institute of Internal Medicine; Oslo University Hospital; Rikshospitalet; Oslo Norway
- Institute of Clinical Medicine; University of Oslo; Oslo Norway
- Department of Haematology; Oslo University Hospital; Rikshospitalet; Oslo Norway
| | - G. E Tjønnfjord
- Research Institute of Internal Medicine; Oslo University Hospital; Rikshospitalet; Oslo Norway
- Institute of Clinical Medicine; University of Oslo; Oslo Norway
- Department of Haematology; Oslo University Hospital; Rikshospitalet; Oslo Norway
| | - P. A. Holme
- Research Institute of Internal Medicine; Oslo University Hospital; Rikshospitalet; Oslo Norway
- Institute of Clinical Medicine; University of Oslo; Oslo Norway
- Department of Haematology; Oslo University Hospital; Rikshospitalet; Oslo Norway
| |
Collapse
|
8
|
Tran HTT, Tjønnfjord GE, Paus A, Holme PA. rFVIIa administered by continuous infusion during surgery in patients with severe congenital FVII deficiency. Haemophilia 2011; 17:764-70. [PMID: 21707871 DOI: 10.1111/j.1365-2516.2011.02596.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The use of recombinant FVIIa (rFVIIa) to control bleed in individuals with FVII deficiency has been proven to be effective. The main problems associated with its use are that it requires frequent bolus injections to counteract its short half-life and high cost. Our study aimed to evaluate whether any advantage could be gained by providing rFVIIa by continuous infusion during surgery with regard to haemostatic efficacy, safety and cost. The prospective study included 10 patients with severe FVII deficiency, who underwent 25 surgical procedures (13 major and 12 minor procedures) and were treated with rFVIIa administered by continuous infusion. Tranexamic acid was given concomitantly every 8 h. Prothrombin time, FVII:C assay and thrombin generation assay were used to monitor the treatment. The mean total dose given was 10 mg during a major surgery and 4.4 mg during a minor surgery for a mean treatment duration of 7.5 and 4.0 days respectively. This corresponds to a reduction of 70-90% in drug usage and medication cost compared with bolus injections. Except for one major perioperative bleeding, excellent haemostasis was achieved in all procedures. One patient developed a transient inhibitory activity. None of these events affected the postoperative course or prolonged the hospital stay. Our study demonstrated that continuous infusion of rFVIIa during surgery is safe, effective and highly cost effective.
Collapse
Affiliation(s)
- H T T Tran
- Research Institute of Internal Medicine Institute of Clinical Medicine, University of Oslo Department of Haematology Department of Orthopedics, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
| | | | | | | |
Collapse
|